Lake Street boosts target for Silk Road Medical shares, optimistic on growth strategy

On Wednesday, Silk Road Medical Inc . (NASDAQ:) shares saw its price target increased by Lake Street Capital Markets to $28.00, a significant jump from the previous $20.00. The firm has maintained a Buy rating on the company’s stock.

The adjustment reflects confidence in the company’s solid foundation and the potential for new sales representatives to effectively integrate into the company’s growth strategy.

The company has been focused on encouraging physicians to adopt a “TCAR first” approach, which aligns with its strategic initiative to deepen market penetration. This strategy, referred to as “go deep,” is expected to leverage the current team’s capabilities to drive further adoption of Silk Road Medical’s offerings.

Despite recent gains in the stock’s value, the analyst at Lake Street Capital Markets believes there is still room for upward movement. This optimism is partly based on the current trading metrics, with Silk Road Medical’s shares trading at approximately 3 times the 2024 estimated enterprise value to revenue (EV/Rev), compared to comparable companies trading around 6 times.

The company’s reassurance to investors about the strength of its foundation and the standard onboarding trajectory for new sales representatives has contributed to the positive outlook. The analyst’s statement highlighted the potential for further upside in the stock’s valuation, reinforcing the Buy rating and the increased price target to $28.00.

InvestingPro Insights

The recent upgrade in Silk Road Medical Inc.’s price target by Lake Street Capital Markets aligns with some of the positive indicators observed in the company’s financial and market performance. According to InvestingPro data, Silk Road Medical has a market capitalization of $682.81 million and has shown a remarkable revenue growth of 27.77% over the last twelve months as of Q4 2023. This growth is complemented by a strong gross profit margin of 71.75%, reflecting the company’s ability to maintain profitability at the core operational level.

Notably, InvestingPro Tips highlight that Silk Road Medical holds more cash than debt on its balance sheet, and analysts have revised their earnings upwards for the upcoming period, signifying potential confidence in the company’s financial health and future performance. However, it’s important to note that analysts do not anticipate the company will be profitable this year and that it has not been profitable over the last twelve months. Despite this, the company has experienced a strong return over the last three months, with a 50.91% price total return, showcasing a significant rebound in investor sentiment.

For those considering further research on Silk Road Medical, there are additional InvestingPro Tips available, which could provide deeper insights into the company’s financial nuances and market potential. By using the coupon code PRONEWS24, interested readers can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription to access these valuable tips and make more informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.


Leave a Comment